Sun, Shu-HuiShu-HuiSunCHIA-HSUIN CHANGZhan, Zhe-WeiZhe-WeiZhanChang, Wen-HsuanWen-HsuanChangChen, Yu-AnYu-AnChenDong, Yaa-HuiYaa-HuiDong2021-12-092021-12-09202111769106https://scholars.lib.ntu.edu.tw/handle/123456789/589731Several observational studies have found that statins may materially decrease the risk of chronic obstructive pulmonary disease (COPD) exacerbations. However, most of these studies used a prevalent user, non-user comparison approach, which may lead to overestimation of the clinical benefits of statins. We aimed to explore the risk of COPD exacerbations associated with statins with a new user, active comparison approach to address potential methodological concerns. We selected fibrates, another class of lipid-lowering agents, as the reference group because no evidence suggests that fibrates have an effect on COPD exacerbations.enactive comparison; acute exacerbations; chronic obstructive pulmonary disease; cohort study; high-dimensional propensity score; new users; statinsActive comparison; Acute exacerbations; Chronic obstructive pulmonary disease; Cohort study; High-dimensional propensity score; New users; Statins[SDGs]SDG3fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; chronic obstructive lung disease; cohort analysis; disease exacerbation; human; propensity score; Cohort Studies; Disease Progression; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Propensity Score; Pulmonary Disease, Chronic Obstructivejournal article10.2147/COPD.S323391346211222-s2.0-85117257173https://api.elsevier.com/content/abstract/scopus_id/85117257173